Elixinol Wellness Ltd · ASX:EXL
Elixinol Wellness — Investor Presentation (October 2020)
23 slides from Elixinol Wellness's investor presentation, Oct 27, 2020
Slide 1: Investor Presentation
Investor Presentation For personal use only October 2020 ASX:EXL | OTC:ELLXF Kind of Amazing 1
Slide 2: Disclaimer
DISCLAIMER For personal use only This presentation contains To the maximum extent permitted by law, no This presentation contains Such forward‐looking statements are based on summary information responsibility for any loss arising in any way from certain forward‐looking statements with numerous abou
Slide 3: Our Vision and Mission
Investor Presentation – October 2020 OUR VISION: For personal use only Building a global, consumer led and Elixinol-branded CBD nutraceuticals business. OUR MISSION: Making a positive contribution to people’s health, wellness and the planet through the power of hemp products. Kind of Amazing 3
Slide 4: What we stand for: Must Wins Values
Investor Presentation – October 2020 What we stand for.... For personal use only MUST WINS VALUES Heritage Global Knowledge Quality & Transparency Compliance Focus Champions in Our global footprint Our products are We maintain a strict hemp for delivers highest quality science & ev idence compliance
Slide 5: Rejuvenated Global Leadership
Investor Presentation – October 2020 Rejuvenated Global Leadership For personal use only To facilitate the turn-around, new leadership capabilities have been put in place at all levels. Specific focus given to augmenting strategic, commercial and governance disciplines. Chair - Helen Wiseman Executi
Slide 6: Repositioned EXL delivers 18% growth
Investor Presentation – October 2020 Repositioned EXL delivers 18%¹ growth For personal use only Robust revenue growth for Q3 across all business units, operating from materially lower cost base following aggressive repositioning efforts. Robust QoQ growth Significant reduction First growth signals
Slide 7: Strategy
STRATEGY For personal use only Kind of Amazing 7 7
Slide 8: Market Outlook & Regulatory Environment
Investor Presentation – October 2020 Market Outlook & Regulatory Environment For personal use only Strong market opportunity across US and Europe Regulation differs across key markets According to Brightfield US regulatory framework uncertain: Group: • Highly competitive and under-regulated market.
Slide 9: Relentless focus on improving fundamentals
Investor Presentation – October 2020 Relentless focus on improving fundamentals For personal use only Strategic efforts continue to be focused on improving cash flow, margin accretion and building new competencies. Cost out / Revenue up Margin Accretion Building New Competencies Q3 Revenue growth 18
Slide 10: Agile and Responsible COVID Response
Investor Presentation – October 2020 Agile and Responsible COVID Response For personal use only Trend toward wellness becoming increasingly important in a COVID-19 environment. Amplify CBD Safeguarding business Channel Shift to E- Responsible capital wellness benefits continuity commerce, TV managem
Slide 11: Continued investment in building global brand
Investor Presentation – October 2020 Continued investment in building global brand For personal use only The NEW Elixinol range is ideally positioned to participate in the global growth of nutraceutical wellness products. UK distribution gains in pharmacy lay foundation for growth. CBD blended capsu
Slide 12: Expanding into high growth CBD Skincare
Investor Presentation – October 2020 Expanding into high growth CBD Skincare For personal use only Our new elixinolSkin CBD skincare range opens new growth channels with fewer regulatory constraints. Boots Ireland secured as first-to-market launch partner. UK Distribution Boots Ireland Launch • Comp
Slide 13: Integrated marketing launch
Investor Presentation – October 2020 Integrated marketing launch For personal use only The Boots Ireland launch has been supported through a multi channel marketing campaign using skincare influencers to drive awareness & education. To-date more than 80k social views and 150k advertising impressions
Slide 14: Consistent growth on improved cost base
Investor Presentation – October 2020 Consistent growth on improved cost base. For personal use only Hemp Foods Australia is one of the most established and well-known hemp foods brands in Australia. Consistent growth with improved margins and leaner operations. Platform to assess AU CBD route to mar
Slide 15: A strengthening global footprint
Investor Presentation – October 2020 A strengthening global footprint For personal use only Our growing global reach offers diversified opportunities and reduces risk. ASIA • Most established and leading brand in Japan • Licensing agreement with Elixinol Japan, supply of HFA products AMERICAS • HFA
Slide 16: Takeaways
Investor Presentation – October 2020 Takeaways For personal use only Elixinol Trusted & Expanding positioned established global presence within brand with break- high growth with fresh through global CBD nutraceuticals distribution in UK categories offering 18% QoQ Optimised Virtually debt Revenue g
Slide 17: Q&A
For personal use only Investor Presentation – October 2020 Q&A Kind of Amazing 17
Slide 18: For More Information
For personal use only Investor Presentation – October 2020 FOR MORE INFORMATION Investor relations and media please contact: Ron Dufficy Chief Financial Officer ron.dufficy@elixinolglobal.com Kind of Amazing 18
Slide 19: Appendix: H1 FY2020 Financial Results
APPENDIX CANNABIS WHO RESULTS BUSINESS FY 2019 FINANCIAL Previous reporting period for reference: DEFINITION WE ARE OVERVIEW OVERVIEW RESULTS OUTLOOK Q+A H1 FY2020 Financial Results For personal use only Kind of Amazing 19
Slide 20: Key Highlights for H1 FY2020
For Reference: H1 FY2020 Results Presentation Key Highlights for H1 FY2020 For personal use only Continued focus on branded consumer goods model and premium margins. Revenue channel mix 31 December year end • H1 FY2020 revenue from continuing operations of $7.9m, down 54% 9% ($17.1m in H1 FY2019) 22
Slide 21: Financial Summary
For Reference: H1 FY2020 Results Presentation Financial Summary For personal use only Continued focus on sales of Elixinol branded products. Revenue • 54% decline H1 FY2020 vs H1 FY2019 driven by: ($m) H1 FY2020 H1 FY2019 • COVID-19 impacts led to challenging retail market conditions Revenue 7.9 17.
Slide 22: Cash Flow
For Reference: H1 FY2020 Results Presentation Cash Flow For personal use only 47% reduction in quarterly operating cash outflows. Operating activities ($m) H1 FY2020 H1 FY2019 • Significant focus t o improve cashflows Operating activities (15.2) (28.9) • 47% reduction in quarterly operating cash out
Slide 23: Financial Position
For Reference: H1 FY2020 Results Presentation Financial Position For personal use only $16.8m cash, virtually no debt, usable inventory to support revenue growth for more than 12 months. ($m) 30 Jun 2020 31 Dec 2019 Curren t assets Cash and cash equivalents 16.8 20.2 Current assets Trade & other rec
Elixinol Wellness — Investor Presentation (October 2020) on 6ix